While large pharma investment in biotechs is down—as pharmas become more strategic in their selections—it is scarcely out, with the partnership dynamic between the two sides remaining strong.
Matthew Arnold
Advertisement
Matthew Arnold is a principal analyst at Clarivate.
Articles by Matthew Arnold
Advertisement
Latest Updated Articles
Biotech’s Survival Story: Companies Bear Down for Lean YearsPublished: July 10th 2023 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
